Dr. Robert Kisilevsky, Department of Pathology at Queen’s University, has been elected as a 2007 fellow of the Royal Society of Canada, Division of Life Sciences.
In keeping with the motto of the society, “Different paths, one vision”, the newly elected fellows, while coming from diverse backgrounds and disciplines, are dedicated to achieving excellence in their endeavours, thus enhancing Canada’s competitiveness on a global basis.
The complete list of newly elected Fellows and their affiliations and citations are available at www.rsc.ca.
Dr. Kisilevsky’s basic studies on abnormal protein folding (amyloid) have led to therapy for some of the important diseases of our time. He has designed agents and drugs to arrest and reverse this process, which are approved for the treatment of amyloidosis, and are in a FDA expedited Phase III clinical trials for the treatment of Alzheimer’s disease. Similar blocking agents are used to treat malaria. Finally, the physiological function of one of these amyloid proteins in cholesterol transport have led to mechanisms to treat atherosclerosis which leads to stroke and heart attacks. Two highly successful biotechnology companies have been founded on his research.
Dr. Kisilevsky was the guest speaker at elorin’s January 2006 Biobreakfast event. He addressed the audience in his capacity as V. P. Research and co-founder of AtheroChem Inc., a regional company founded in January 2004 by Queen’s University researchers and PARTEQ Innovations. AtheroChem Inc. is developing novel compounds for the treatment of coronary heart disease caused by atherosclerosis and is dedicated to bringing its technologies from the research laboratory to clinic.
Founded in 1882, RSC is Canada’s oldest and most prestigious scholarly organization. Election to RSC is the highest honour that can be attained by scholars, artists and scientists in Canada.